{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"53","value":"6"}]}]}],"denomUnitsSelected":"Resolved Events","denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"44"}],"units":"Resolved Events"}],"description":"Clinically Meaningful Event is defined as an event that is grade \\>= 2 for which BLENREP administration is halted until the event resolves to grade \\<= 1. Time to resolution is calculated for events that resolved. Unresolved events are those that had not returned to grade \\<=1 at last contact due to either end of study or lost to ophthalmologic follow-up. There were 44 Resolved events for changes in Best Corrected Visual Acuity that were analyzed.","dispersionType":"Full Range","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023","id":"OG000","title":"Multiple Myeloma/Blenrep Participants"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Ophthalmology: Time to Resolution of Clinically Meaningful Ocular Toxicities - Best Corrected Visual Acuity","type":"POST_HOC","typeUnitsAnalyzed":"Resolved Events","unitOfMeasure":"Weeks"}